SCHEMBL10205192

SCHEMBL10205192

CSCCN1CCC(c2ccc(Nc3ncc(Cl)c(NCc4cccc5c4C(C)(C)C(=O)N5)n3)c(C)c2)CC1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 8/20 0.42
▸ ALK Q9UM73 5/20 0.39
▸ INSR P06213 3/20 0.39
▸ IGF1R P08069 1/20 0.39
▸ FLT4 P35916 1/20 0.38
▸ PTK2 Q05397 1/20 0.38
▸ TNK2 Q07912 2/20 0.38
▸ BTK Q06187 3/20 0.38
▸ JAK3 P52333 3/20 0.38
▸ LRRK2 Q5S007 2/20 0.37
▸ KCNH2 Q12809 1/20 0.36
▸ JAK2 O60674 2/20 0.36
▸ JAK1 P23458 1/20 0.36
▸ TTK P33981 1/20 0.36
▸ FLT3 P36888 1/20 0.36
▸ TXK P42681 1/20 0.36
▸ BLK P51451 1/20 0.36
▸ ITK Q08881 1/20 0.36
▸ SRC P12931 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10205190 0.92 EGFR (0.51) EGFRALKINSRIGF1RFLT4
SCHEMBL10205209 0.91 ALK (0.47) EGFRALKINSRIGF1RFLT4
SCHEMBL10205181 0.91 EGFR (0.45) EGFRALKINSRIGF1RTNK2
SCHEMBL10207086 0.90 EGFR (0.41) EGFRALKINSRIGF1RFLT4
SCHEMBL14331739 0.90 EGFR (0.46) EGFRALKINSRIGF1RFLT4
SCHEMBL10206626 0.90 STK17A (0.42) EGFRALKFLT4PTK2TNK2
SCHEMBL16255604 0.89 FLT4 (0.41) EGFRALKINSRIGF1RFLT4
SCHEMBL14331737 0.88 EGFR (0.40) EGFRALKINSRIGF1RFLT4
SCHEMBL10205180 0.88 EGFR (0.41) EGFRALKINSRIGF1RFLT4
SCHEMBL10205935 0.88 ALK (0.45) EGFRALKINSRFLT4PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012085126-A1 OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-28 — — WO disclosed
Send feedback